In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Research Reveals Strong 7.7% CAGR Outlook Through 2030

The in vitro diagnostic (IVD) market focused on cardiology and neurology is positioned for impressive expansion as advancements in healthcare technologies and rising patient needs drive demand. This sector is becoming increasingly vital due to the growing emphasis on early and accurate disease detection, personalized diagnostic solutions, and innovative testing methods. Let's explore the market size forecast, key players, influential trends, and detailed segment insights to better understand where this industry is headed.

Expected Market Growth and Size of the IVD in Cardiology and Neurology Market
The market for in vitro diagnostics in cardiology and neurology is projected to grow substantially, reaching a valuation of $25.18 billion by 2030. This expansion is anticipated to occur at a compound annual growth rate (CAGR) of 7.7%, driven by several key factors. An aging global population, increasing demand for personalized diagnostic tools, and wider availability of point-of-care testing facilities are among the top contributors. Additionally, rising healthcare spending in emerging economies and the growing adoption of molecular diagnostics further support this upward trajectory. Key trends expected to influence this market include a heightened focus on early disease detection, increased use of point-of-care cardiac and neurological tests, broader biomarker-based diagnostic methods, and a shift toward preventive and predictive testing strategies, including the integration of multi-parameter diagnostic panels.

The in vitro diagnostic (ivd) in cardiology and neurology market size has grown strongly in recent years. It will grow from $17.22 billion in 2025 to $18.71 billion in 2026 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to rising prevalence of cardiovascular diseases, increasing incidence of neurological disorders, growth of hospital diagnostic infrastructure, advancements in immunoassay technologies, increased clinical awareness of early diagnosis.

Download a free sample of the in vitro diagnostic (ivd) in cardiology and neurology market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15829&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Top Companies Leading the IVD Market in Cardiology and Neurology
Several prominent companies dominate the in vitro diagnostic space for cardiology and neurology, shaping innovation and market direction. These include F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton dic*kinson And Company, Quest Diagnostics Incorporated, Hologic Inc., Illumina Inc., Beckman Coulter Inc., Quidel Corporation, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Instrumentation Laboratory, bioMérieux SA, Natera, Inc., Randox Laboratories Ltd., Fulgent Genetics Inc., DiaSorin S.p.A., Oxford Nanopore Technologies, Fujirebio Diagnostics Inc., Adaptive Biotechnologies, Biocartis Group NV, and Agena Bioscience.

A notable recent development occurred in March 2024, when Beckman Coulter, a US-based firm specializing in laboratory diagnostics, expanded its collaboration with Japan-based Fujirebio. This partnership focuses on enhancing the development, production, and clinical implementation of neurodegenerative disease assays. By combining their expertise in diagnostics and neurological biomarkers, the companies aim to improve patient outcomes through more precise and timely diagnostic solutions.

View the full in vitro diagnostic (ivd) in cardiology and neurology market report:
https://www.thebusinessresearchcompany.com/report/in-vitro-diagnostic-ivd-in-cardiology-and-neurology-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Emerging Trends Shaping the Future of the IVD Market in Cardiology and Neurology
Leading companies are increasingly investing in artificial intelligence (AI)-enabled epigenetic engines designed for early detection and risk evaluation of diseases. These integrated AI systems utilize machine learning alongside advanced biomarker analysis to boost diagnostic accuracy and sensitivity for cardiovascular conditions, addressing key factors in disease progression. For example, in February 2023, the US biotechnology firm Cardio Diagnostics Holdings Inc. introduced PrecisionCHD, an AI-powered blood test targeting early coronary heart disease (CHD) detection. This test employs an integrated epigenetic and genetic engine to assess CHD risk and aims to prevent or identify this prevalent cardiovascular disease sooner. Combining biomarkers with machine-learning algorithms, PrecisionCHD achieves over 75% sensitivity in men and women alike. It also connects patient biomarker profiles with modifiable risk factors such as smoking, diabetes, hypertension, and high cholesterol, offering a non-invasive alternative to traditional exercise stress tests or angiograms. Blood samples can be collected either in medical offices or at home, enhancing patient convenience.

Detailed Segmentation of the IVD Market in Cardiology and Neurology
This market is categorized across multiple dimensions to provide a comprehensive overview:
1) By Product Type:
- Instruments
- Reagents and Consumables
- Software and Services
2) By Technology:
- Immunoassays
- Molecular Diagnostics
- Hematology
- Other Technologies
3) By End-User:
- Hospitals
- Clinical Laboratories
- Other End-Users

Further breakdowns include:
- Instruments: Diagnostic Analyzers, Point-of-Care Devices
- Reagents and Consumables: Diagnostic Reagents, Test Kits, Assay Consumables
- Software and Services: Diagnostic Software, Data Management Software, IVD Consulting and Support Services

This detailed segmentation highlights the extensive range of products, technologies, and users involved, reflecting the complexity and diversity within the cardiology and neurology IVD market.

Our latest 2026 market reports provide expanded strategic and visual intelligence with market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, together with updated graphics and tables.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.